Diabetes, Vol 34, Issue 3 222-234, Copyright © 1985 by American Diabetes Association

ARTICLES

The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus

WT Garvey, JM Olefsky, J Griffin, RF Hamman and OG Kolterman

We have studied the effects of 3 wk of continuous subcutaneous insulin infusion (CSII) on endogenous insulin secretion and action in a group of 14 type II diabetic subjects with a mean (+/-SEM) fasting glucose level of 286 +/- 17 mg/dl. Normal basal and postprandial glucose levels were achieved during insulin therapy at the expense of marked peripheral hyperinsulinemia. During the week of posttreatment evaluation, the subjects maintained a mean fasting glucose level of 155 +/- 11 mg/dl off insulin therapy, indicating a persistent improvement in carbohydrate homeostasis. Adipocyte insulin binding and in vivo insulin dose-response curves for glucose disposal using the euglycemic clamp technique were measured before and after therapy to assess the effect on receptor and postreceptor insulin action. Adipocyte insulin binding did not change. The insulin dose-response curve for overall glucose disposal remained right-shifted compared with age-matched controls, but the mean maximal glucose disposal rate increased by 74% from 160 +/- 14 to 278 +/- 18 mg/m2/min (P less than 0.0005). The effect of insulin treatment on basal hepatic glucose output was also assessed; the mean rate was initially elevated at 159 +/- 8 mg/m2/min but fell to 90 +/- 5 mg/m2/min in the posttreatment period (P less than 0.001), a value similar to that in control subjects. Endogenous insulin secretion was assessed in detail and found to be improved after exogenous insulin therapy. Mean 24-h integrated serum insulin and C-peptide concentrations were increased from 21,377 +/- 2766 to 35,584 +/- 4549 microU/ml/min (P less than 0.01) and from 1653 +/- 215 to 2112 +/- 188 pmol/ml/min (P less than 0.05), respectively, despite lower glycemia. Second-phase insulin response to an intravenous (i.v.) glucose challenge was enhanced from 170 +/- 53 to 1022 +/- 376 microU/ml/min (P less than 0.025), although first-phase response remained minimal. Finally, the mean insulin and C-peptide responses to an i.v. glucagon pulse were unchanged in the posttreatment period, but when glucose levels were increased by exogenous glucose infusion to approximate the levels observed before therapy and the glucagon pulse repeated, responses were markedly enhanced. Simple and multivariate correlation analysis showed that only measures of basal hepatic glucose output and the magnitude of the postbinding defect in the untreated state could be related to the respective fasting glucose levels in individual subjects.(ABSTRACT TRUNCATED AT 400 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. L. Leahy Mary, Mary, Quite Contrary, How Do Your {beta}-Cells Fail? Diabetes, October 1, 2008; 57(10): 2563 - 2564. [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835. [Abstract] [Full Text] [PDF]

				S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S. [Full Text] [PDF]

				M. A. Abdul-Ghani, D. Tripathy, and R. A. DeFronzo Contributions of {beta}-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose Diabetes Care, May 1, 2006; 29(5): 1130 - 1139. [Abstract] [Full Text] [PDF]

				C. Lara-Castro, N. Luo, P. Wallace, R. L. Klein, and W. T. Garvey Adiponectin Multimeric Complexes and the Metabolic Syndrome Trait Cluster Diabetes, January 1, 2006; 55(1): 249 - 259. [Abstract] [Full Text] [PDF]

				M. B. Davidson Early Insulin Therapy for Type 2 Diabetic Patients: More Cost Than Benefit Diabetes Care, January 1, 2005; 28(1): 222 - 224. [Full Text] [PDF]

				N. Rasouli and S. C. Elbein Improved Glycemic Control in Subjects with Atypical Diabetes Results from Restored Insulin Secretion, But Not Improved Insulin Sensitivity J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6331 - 6335. [Abstract] [Full Text] [PDF]

				K. Yoshioka, T. Yoshida, and T. Yoshikawa Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes: Response to Ryan, Imes, and Wallace Diabetes Care, September 1, 2004; 27(9): 2281 - 2282. [Full Text] [PDF]

				E. A. Ryan, S. Imes, and C. Wallace Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Diabetes Care, May 1, 2004; 27(5): 1028 - 1032. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Kwon, S. Shaughnessy, P. Wallace, A. Hutto, A. J. Jenkins, R. L. Klein, and W. T. Garvey Critical Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance With Dyslipidemia Diabetes Care, April 1, 2004; 27(4): 978 - 983. [Abstract] [Full Text] [PDF]

				E. V. Polyzogopoulou, F. Kalfarentzos, A. G. Vagenakis, and T. K. Alexandrides Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery Diabetes, May 1, 2003; 52(5): 1098 - 1103. [Abstract] [Full Text] [PDF]

				W. T. Garvey, S. Kwon, D. Zheng, S. Shaughnessy, P. Wallace, A. Hutto, K. Pugh, A. J. Jenkins, R. L. Klein, and Y. Liao Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance Diabetes, February 1, 2003; 52(2): 453 - 462. [Abstract] [Full Text] [PDF]

				D. R. Laybutt, M. Glandt, G. Xu, Y. B. Ahn, N. Trivedi, S. Bonner-Weir, and G. C. Weir Critical Reduction in beta -Cell Mass Results in Two Distinct Outcomes over Time. ADAPTATION WITH IMPAIRED GLUCOSE TOLERANCE OR DECOMPENSATED DIABETES J. Biol. Chem., January 24, 2003; 278(5): 2997 - 3005. [Abstract] [Full Text] [PDF]

				J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson Clarifying the Role of Insulin in Type 2 Diabetes Management Clin. Diabetes, January 1, 2003; 21(1): 14 - 21. [Abstract] [Full Text] [PDF]

				S. M. Willi, A. Kennedy, P. Wallace, E. Ganaway, N. L. Rogers, and W. T. Garvey Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans: Effects on Glucose Tolerance, Insulin Sensitivity, Suppression of Free Fatty Acids, and Leptin Diabetes, October 1, 2002; 51(10): 2895 - 2902. [Abstract] [Full Text] [PDF]

				C. Anderwald, E. Bernroider, M. Krssak, H. Stingl, A. Brehm, M. G. Bischof, P. Nowotny, M. Roden, and W. Waldhausl Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle Diabetes, October 1, 2002; 51(10): 3025 - 3032. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care, September 1, 2002; 25(9): 1644 - 1649. [Full Text] [PDF]

				T. Pratipanawatr, K. Cusi, P. Ngo, W. Pratipanawatr, L. J. Mandarino, and R. A. DeFronzo Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes Diabetes, February 1, 2002; 51(2): 462 - 468. [Abstract] [Full Text] [PDF]

				E. Toschi, S. Camastra, A. M. Sironi, A. Masoni, A. Gastaldelli, A. Mari, E. Ferrannini, and A. Natali Effect of Acute Hyperglycemia on Insulin Secretion in Humans Diabetes, February 1, 2002; 51(90001): S130 - 133. [Abstract] [Full Text] [PDF]

				M. Gaster, P. Staehr, H. Beck-Nielsen, H. D. Schrøder, and A. Handberg GLUT4 Is Reduced in Slow Muscle Fibers of Type 2 Diabetic Patients: Is Insulin Resistance in Type 2 Diabetes a Slow, Type 1 Fiber Disease? Diabetes, June 1, 2001; 50(6): 1324 - 1329. [Abstract] [Full Text]

				D. M. Nathan Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? Ann Intern Med, February 6, 2001; 134(3): 242 - 244. [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				T. Laedtke, L. Kjems, N. Porksen, O. Schmitz, J. Veldhuis, P. C. Kao, and P. C. Butler Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E520 - E528. [Abstract] [Full Text] [PDF]

				Z. K. Krowicki, N. A. Nathan, and P. J. Hornby Gastric motor and cardiovascular effects of insulin in dorsal vagal complex of the rat Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G964 - G972. [Abstract] [Full Text] [PDF]

				H. R. Robert Glucose Control and Insulin Resistance in Non-Insulin-dependent Diabetes Mellitus Ann Intern Med, January 1, 1996; 124(1_Part_2): 97 - 103. [Abstract] [Full Text]

				J. A. Colwell The Feasibility of Intensive Insulin Management in Non-Insulin-dependent Diabetes Mellitus: Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM Ann Intern Med, January 1, 1996; 124(1_Part_2): 131 - 135. [Abstract] [Full Text]